Engineered mad7 directed endonuclease
AssigneeBio-Techne Corporation
InventorsBryan Jones, Neil Otto, Blake Barnes
Life of this patent
Estimating the term…
Abstract
The present disclosure provides CRISPR systems using engineered MAD7 endonucleases, as well as methods, vectors, nucleic acid compositions, and kits thereof. In particular, provided herein are MAD7 nickases, catalytically dead MAD7 enzymes, and hyperactive MAD7 enzymes.
Claims36
A modified MAD7 enzyme comprising a mutation in one or more catalytic domains, wherein the modified MAD7 enzyme possesses nickase activity.
A modified MAD7 enzyme comprising a mutation in one or more catalytic domains, wherein the enzyme is catalytically inactive.
A modified MAD7 enzyme, wherein the enzyme comprises a mutation in a domain selected from a PAM binding domain, a RuvC endonuclease domain, and a nuclease domain, wherein the enzyme possesses increased nuclease activity compared to wild-type MAD7 enzyme.
A fusion protein comprising the modified MAD7 enzyme of any of the preceding claims.
The system of any of the preceding claims, wherein the target DNA sequence is a genomic DNA sequence in a host cell.
Dependencies are inferred from the claim text.